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Abstract
Objective In view of mobile phone exposure being classified as a
possible human carcinogen by the International Agency for Research
on Cancer (IARC), we determined the compatibility of two recent reports
of glioma risk (forming the basis of the IARC’s classification) with
observed incidence trends in the United States.
Design Comparison of observed rates with projected rates of glioma
incidence for 1997-2008. We estimated projected rates by combining
relative risks reported in the 2010 Interphone study and a 2011 Swedish
study by Hardell and colleagues with rates adjusted for age, registry,
and sex; data for mobile phone use; and various latency periods.
Setting US population based data for glioma incidence in 1992-2008,
from 12 registries in the Surveillance, Epidemiology, and End Results
(SEER) programme (Atlanta, Detroit, Los Angeles, San Francisco, San
Jose-Monterey, Seattle, rural Georgia, Connecticut, Hawaii, Iowa, New
Mexico, and Utah).
Participants Data for 24 813 non-Hispanic white people diagnosed with
glioma at age 18 years or older.
Results Age specific incidence rates of glioma remained generally
constant in 1992-2008 (−0.02% change per year, 95% confidence interval
−0.28% to 0.25%), a period coinciding with a substantial increase in
mobile phone use from close to 0% to almost 100% of the US population.
If phone use was associated with glioma risk, we expected glioma
incidence rates to be higher than those observed, even with a latency
period of 10 years and low relative risks (1.5). Based on relative risks
of glioma by tumour latency and cumulative hours of phone use in the
Swedish study, predicted rates should have been at least 40% higher
than observed rates in 2008. However, predicted glioma rates based on
the small proportion of highly exposed people in the Interphone study
could be consistent with the observed data. Results remained valid if
we used either non-regular users or low users of mobile phones as the
baseline category, and if we constrained relative risks to be more than
1.
Conclusions Raised risks of glioma with mobile phone use, as reported
by one (Swedish) study forming the basis of the IARC’s re-evaluation
of mobile phone exposure, are not consistent with observed incidence
trends in US population data, although the US data could be consistent
with the modest excess risks in the Interphone study.
Introduction
The association between microwave radiation exposure from
mobile phone use and tumour development in the brain and
centralnervoussystemhasbeenmuchinvestigated,yetremains
controversial. Although many large and well conducted studies
havefoundlittleevidencetosupportsuchalink,
1-5afewstudies
have observed modest to large increases in relative risk,
6-11
generally of glioma but with some reports of acoustic
neuroma.
9 11 Results have been generally negative for an
association between phone use and risk of meningioma.
12 The
International Agency for Research on Cancer (IARC) has
recently re-evaluated the risk of tumour development in the
brain and central nervous system from mobile phone use, and
rated this type of exposure as a possible human carcinogen
(grade 2B).
12 This declaration was based mainly on the results
of two epidemiological studies: the Interphone study
4 and a
recent Swedish study by Hardell and colleagues.
10
Temporal trends in brain tumour incidence could add valuable
datatotheresultsofanalyticalepidemiologicalstudiesassessing
exposuresthathavechangedovertime,suchastheuseofmobile
phones. A large study in the United States
13 assessed trends in
brain cancer incidence in 1973-2006, and observed general
reductions in incidence rates in 1992-2006. Compared with the
marked increase in ownership and use of mobile phones in the
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Research
RESEARCHUS over this same period, the reductions did not support the
notion that phone use causes brain cancer. In a study of brain
cancer incidence in Scandinavia in 1974-2004, researchers
observed gradually rising rates that did not correspond with the
substantial increase in mobile phone use in the late 1990s,
14
again implying no strong association.
A study in the United Kingdom observed no changes over the
period 1998-2007 in the total incidence of brain cancer overall,
nor for any sex or age group.
15 Although researchers saw an
increasing trend in cancer of the temporal lobe, this trend had
begun in the late 1970s, with no change in rate in recent years;
therefore,theseresultswereunlikelytosupportthecarcinogenic
effect of mobile phone exposure.
16 A similar survey of glioma
incidence rates in Swedish adults in 1970-2009 yielded no
evidence of changing rates over time for various age groups.
17
However,noneofthesestudies
13-15 17assessedthepotentialeffect
of latency or possible variation in excess relative risk with the
cumulative duration of phone use on trends in brain cancer
incidence.
In this study, we compared the observed patterns for glioma
incidence trends in the US in 1992-2008 with projected
incidence rates for the same period based on relative risks
reported by the two epidemiological studies forming the basis
oftheIARCWorkingGroupclassification.
4 10Ourcomparisons
considered hypothesised latency periods, anatomical sites, and
glioma grades, and we also took account of changes in mobile
phone use during this period.
Methods
Data collection
We used incidence data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER)
programme that compiles information from a series of
populationbasedcancerregistriesthroughouttheUS.
18Because
incidence rates vary by race and origin, and the population
composition has changed over time, we focused our analysis
on non-Hispanic white people (although subsidiary analysis
was conducted of other ethnic groups). Hispanicity as well as
race has been recorded since 1992 among residents of the areas
inthe12SEERregistriesusedinthisanalysis(Atlanta,Detroit,
Los Angeles, San Francisco, San Jose-Monterey, Seattle, rural
Georgia,Connecticut,Hawaii,Iowa,NewMexico,andUtah).
19
Primary site and histological type of the cancers were coded
according to the International Classification of Diseases, 3rd
edition (ICD-3), from 1992 onwards.
20 We selected all 28 850
diagnoses of brain cancer (ICD-3 topography codes
C71.0-C71.9, behaviour 3, excluding brain lymphomas) in
non-Hispanicwhitepeoplein1992-2008.Wefocusedonglioma
(ICD-3 morphology codes 9380-9480), but also looked at
astrocytoma (9400-9421, 9424, 9440-9442),
21 a subgroup of
gliomas that was assessed in detail in the Swedish study,
although the study did not specify their exact codes.
10 Most
studies of brain cancer have focused on glioma in relation to
mobile phone use
2-4 6 9 10 (web appendix, table A1). Clinically,
gliomaisthemostcommoncategoryofbraincancer,andamong
those with the worst prognosis. Survival at five years is less
than 50% for adults, and only 2.9% for glioblastoma, the most
common histological subtype.
22 These survival rates fall
substantiallywithincreasingage,
18althoughsomepatientswith
low grade glioma have had rates approaching 60%.
23
Weanalyseddatafor27457casesofglioma.Sincemoststudies
of mobile phone use and glioma have concentrated on
adults,
2-4 7 10 we concentrated on the 24 813 people diagnosed
with glioma at age 18 years or older (table 1⇓). We further
categorisedgliomasbyprimaryanatomicalsiteandgrade,based
ontheWorldHealthOrganization’sbraintumourclassification.
24
We considered astrocytoma separately. We also did summary
cross tabulations of the numbers of glioma and the underlying
populationbyage,sex,andSEERregistry(webappendix,tables
A2 and A3).
We downloaded data for mobile phone subscriptions per year
in the US in 1985-2010 from the Cellular Telecommunications
InternationalAssociation’swebsite.
25Minimumlatencyperiods
of up to 10 years are thought to apply for mobile phone
exposure
4 10; therefore, we assessed subscriptions from 1982
onwards, for evaluation of glioma incidence from 1992 up to
2008. We estimated data for 1982-4 by log linear regression,
with the assumption that the number of subscriptions per year
wasapproximatelyCexp[αyear](whereCandαareparameters
determined by the regression). More specifically, we fitted a
modelviaordinaryleastsquarestolog[numberofsubscriptions
per year], using subscriptions data for 1985-90. We estimated
thenumberofsubscriptionspercapitaforeachyearbydividing
the number of subscriptions by the total US population in that
year (fig 1⇓).
26
Statistical methods
Substantial mobile phone use only began in the mid-1990s (fig
1), and preliminary Poisson model fitting did not suggest that
glioma rates in the 1990s varied greatly. Therefore, we fitted a
model that estimated glioma rates in 1992-6 (assumed to be
constantandlargelyindependentofmobilephoneuse)andthen
in separate years from 1997 to 2008, adjusted for age group,
specific SEER registry, and sex. We used model fitted rates to
estimate observed rates, rather than crude rates, to avoid the
introductionoferrorsfromchangesintheunderlyingpopulation
distribution (by age, sex, and registry). Model observed rates
of glioma were estimated using men aged 60-64 years from the
Los Angeles SEER registry as the baseline categories (web
appendix, model A1), but the entire dataset (all ages ≥18 years,
sexes, registries) was used to estimate these rates using this
model. The reason for using these baseline categories is given
inthewebappendix.WefittedthemodelbyPoissonmaximum
likelihood
27 using Epicure (web appendix).
28
Wecalculatedpredictedrisksofgliomawith(everversusnever)
mobile phone use in 1997-2008 by combining the estimated
rates of glioma in 1992-6, the number of phone subscriptions
per capita, and various assumed relative risks associated with
ever using a phone and latency periods (fig 2⇓). In figure 2, we
also included a line corresponding to a relative risk of 0.8
(approximately corresponding to what was observed in the
Interphone study).
4
We further estimated the predicted rates by combining the
number of mobile phone subscriptions with the relative risks
by latency period and cumulative hours of phone use estimated
in the Swedish study
10 and Interphone study
4 (web appendix,
model A2). We assumed that the cumulative hours of phone
use in the US population had the same distribution as that in
the control groups in each study, as shown in tables 2-4⇓ ⇓ ⇓.
Wecomparedtheseprojectedratesofgliomaforeachyearfrom
1997 onwards, with the corresponding “observed” rates
predicted by the model (that had adjusted for age, registry, and
sex) (figs 3⇓ and 4⇓, tables 5⇓). We also used predicted data
from appendix 2 of the Interphone study
4 (tables 4 and 6⇓),
which calculated risks relative to low use categories of mobile
phone users (rather than the non-regular users used in the main
analysis). We did this additional analysis to minimise potential
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RESEARCHbiasthathadbeenindicatedbytheJshapeddose-responsecurve
in the Interphone study.
4 However, when predicting the risk of
US glioma incidence in table 6, we assumed that these relative
risks were relative to the group of non-users of mobile phones.
Because many relative risks of exposed people, compared with
non-exposed people, were less than 1 in the Interphone study
4
(implying an unexpected protective effect of phone use), we
also estimated rates assuming that Interphone study risks were
1 or more (thus setting all relative risks less than 1 to 1), which
assumes no protective effects in any category. The reporting of
ourstudyconformstotheSTROBEstatement
29(webappendix,
table A4).
Results
Gliomaratesweregenerallystablefrom1992to2008(figs2-4,
table 5), changing by about −0.02% per year (95% confidence
interval−0.28%to0.25%)overthisperiod(table7⇓).Theonly
marked exceptions were gliomas of low grade and those with
apoorlyspecifiedanatomicallocation,whichshoweddecreased
rates (−3.02% per year (−3.49 to −2.54) and −2.35% per year
(−2.81 to −1.89), respectively), and gliomas of the temporal
lobe and other specified sites, which showed modest increases
inrates(0.73%peryear(0.23to1.23)and0.79%peryear(0.40
to 1.19), respectively) (figs 3 and 4, tables 5 and 7). However,
we saw no acceleration in the rate of gliomas at the temporal
lobe(P=0.279)oratotherspecifiedsites(P=0.090)before1996
compared with after 1996 (results not shown). Equally, we saw
no evidence to indicate a decrease in glioma risk by about 20%
(that is, a relative risk of 0.8), which had been indicated by the
Interphone study for regular users of mobile phones.
The result of assuming a true association of mobile phone use
greatly increased the expected glioma rates. Even with a lag of
10yearsandthesmallestassumedrelativeriskmorethan1that
was associated with ever using a phone (that is, a relative risk
of 1.5), the underlying glioma rate estimated by age, registry,
andsexwaspredictedtoincreasefrom17.7per100000people
per year (95% confidence interval 16.7 to 18.7) in 1992-6 to
19.5 per 100 000 people per year (18.5 to 20.7) in 2008, an
increase of 10.7% (fig 2). With greater relative risks or shorter
lagperiods,thisincreasebecamemuchlarger.Ingeneral,glioma
rates were predicted to increase by at least 20% with a short
latency period (≤5 years) or large relative risks (≥2.0) (fig 2).
Predicted rates were substantially more than observed rates if
weappliedtherelativerisksoftheSwedishstudy
10tothe1992-6
baseline rates (and took account of the distribution by latency
periodsandcumulativephoneusereported),andifweaccounted
for the increasing per capita prevalence of mobile phone use
(figs 3-4, table 5). For example, the observed rate for glioma in
2008 was 17.7 per 100 000 people per year (95% confidence
interval 16.5 to 19.0), whereas the projected rate in that year,
assumingthattheSwedishstudy’srelativerisksassociatedwith
mobile phone use apply, was 44.5% higher than the observed
rate (25.5 per 100 000 people per year (24.2 to 27.0)), and
clearly inconsistent with it. In general, the model predicted the
same or greater effects for astrocytoma only (fig 3, table 5),
variousgradesofglioma(fig3,table4),anddifferentanatomical
sites(fig4,table5).ResultsweresimilarifweusedtheSwedish
study’s“everversusneveruse”data
10ratherthanthedatataking
account of cumulative hours of phone use (results not shown).
However, if we used the relative risks from the Interphone
study,
4 the expected incidence rate of glioma in 2008 changed
to 16.5 per 100 000 people per year (95% confidence interval
15.6 to 17.5), compared with the observed rate of 17.7 per 100
000 people per year, or 18.2 per 100 000 people per year (95%
confidence interval 17.3 to 19.3) if we restricted excess risks to
be positive (that is, relative risk ≥1) (fig 3, table 5). The
confidence intervals around the glioma rates implied that the
observed trends were consistent with those predicted by the
Interphone study; we observed the same effect if we used the
relative risks taken from appendix 2 of the Interphone study
4
(table 6). We saw similar results for specific groups aged 40 to
69 years (web appendix, table A5 and fig A1). Results were
also similar for different categories of sex, or race (web
appendix,tablesA6-A10)anddifferingbaselineperiods(1992-5
or 1992-7; results not shown).
Discussion
The results of this study suggest that, if the effects of mobile
phones on malignant glioma risk are substantial, then the
incidence rates in the US population would be far higher than
those observed over most of the study period in 1992-2008 (fig
2). Although we cannot rule out modest increases in glioma
incidencesince1992,increasesof20%ormorethatmightoccur
if the latency period was short (≤5 years) or relative risk was
large (≥2.0) were inconsistent with the observed SEER data.
UsingtherelativerisksfromtheSwedishstudy
10andaccounting
for the substantial increase in phone use in 1992-2008, our
alternative analysis predicted that glioma rates should be about
44% higher than the observed incidence rates for 2008.
However, if we used the relative risks from the Interphone
study,
4theincreaseinmobilephoneusein1992-2008predicted
a modest reduction in glioma incidence of about 7% (or an
increaseofabout3%ifassumingrelativerisks≥1);theseresults
were consistent with the observed rate. However, we did not
find evidence supporting the overall reduction of about 19%
when comparing ever use and never use groups, as implied by
the Interphone study (fig 2). The J shaped dose-response curve
in the Interphone study, of which this 19% reduction is one
indicator,hasbeenusedtoargueforpossibleparticipationbias,
implying that risks ought to be estimated relative to the lowest
use group, rather than to non-users (that is, using the results
fromappendix2ofthestudy).
4Thefindingsbasedonappendix
2oftheInterphonestudywereconsistentwithobservedglioma
trends (tables 5 and 6).
Without data indicating substantial effects of mobile phone
exposure on incidence rates of brain cancer,
1-5 it is not possible
to accurately estimate the minimum latency period. Ionising
radiationisgenerallyassumedtohaveaminimumlatencyperiod
of 2-5 years.
30 31 The induction of cancer is thought to occur
largely by the initiation of DNA lesions.
32 In particular, clinical
evidencehasshownclonalDNAmutationsinbraintumours,
33-36
implying that DNA damage could be the initiating event.
Ionising radiation, which is known to induce brain cancer,
30 is
thought to do so by initiating large scale chromosomal damage
resulting from DNA breakage and rearrangement.
32
Since microwave radiation produced by mobile phones is
non-ionising and therefore not strong enough to cause DNA
lesionsdirectly,itprobablyactslaterinthecarcinogenicprocess.
Thiseffectimpliesthattheminimumlatencyperiodforradiation
produced by mobile phones is probably shorter than that for
ionising radiation (that is, <5 years). However, since the cause
of brain cancer is still unclear, we could not definitively state a
minimum latency period, and therefore considered several
periods between 1 and 10 years, similar to other studies.
4 10 The
Swedishstudy
10suggestedaminimumlatencyperiodofatleast
10 years (table 2; web appendix, table A1). This result is
puzzling, because the study used data for people diagnosed in
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RESEARCH1997-2003, and mobile phone use in Sweden only began to be
appreciable only in the mid to late 1990s.
14 17
Several scientific groups have reviewed the experimental in
vivo and in vitro data available for microwave exposure from
mobile phone use.
12 37 No compelling data have suggested that
microwaveexposurecanincreasetheriskofanytypeofcancer,
or raise rates of somatic or germ cell mutation.
37 In particular,
astudyof480Fischerratsdidnotfindanyexcessriskofglioma
orastrocytomainthoseexposedto835.62MHzor847.74MHz
ofmicrowaveradiation.
38However,thestudy’sstatisticalpower
for astrocytoma was probably low, because the 160 controls
had a 1% prevalence.
Strengths and limitations of the study
This study used population based incidence data from the well
regarded SEER programme. The SEER data’s high quality was
evidenced by the completeness of case ascertainment and the
accurate classification of cancer sites and histological types.
However, the appropriate exposure measure for brain cancer is
still unclear in relation to mobile phone use. A widely used
method is to use an “ever versus never use” comparison.
1-9
Metrics based on the duration of mobile phone use have also
beenused—thatis,thenumberofminutesperdayofoperation,
duration of use (in years), or cumulative period of use (in
hours).
1 2 4 7 8 10Weusedamodelbasedonan“everversusnever
use” comparison (fig 2) and another based on the cumulative
hoursofmobilephoneuse(figs3and4,table4).(Ourdefinition
of “ever use” was based on the ownership of a phone, whereas
theInterphonestudydefined“everuse”asanaverageofatleast
one phone call per week for six months or more, based on
interview data from individuals.
4) We used both models in
conjunction with data for phone subscriptions gathered for the
US as a whole,
25 to assess the effect of mobile phone use on
glioma incidence.
Subscription data may have slightly underestimated the
proportion of people who were mobile phone users, because
people might have used a phone without being a subscriber.
More likely, the data could have overestimated the proportion,
becausesomeindividualsmighthavehadmultiplesubscriptions.
Thenumberofsubscribersin2011exceededtheUSpopulation
by about 2%,
25 implying that the estimate was unlikely to be
substantiallyinerrordownwards,andwesuspectalsoupwards.
The area covered by the SEER registries might not have
representedtheUSasawholeinitsownershipanduseofmobile
phones. Furthermore, the age distribution of users might not
havematchedthatoftheunderlyingSEERpopulation,although
the two cannot be very different towards the end of the period
consideredwhenownershipapproached100%ofthepopulation.
The second model used was slightly more sophisticated, and
used estimates of relative risk for specific classes of latency
periods and cumulative hours of phone use reported by the
Swedish study
10 and Interphone study.
4 We used both models
to predict cancer rates (particularly for the period 1997-2008),
with data for mobile phone ownership. A critical assumption
of both models was that the underlying cancer rates (in the
absence of phone use) remained constant at the levels
determined for the period 1992-6, when use was relatively
modest. However, for low grade tumours and those of poorly
specified anatomical location, incidence seemed to decrease in
1992-2008 (figs 3 and 4), so this assumption might not have
been valid for these endpoints. The reduction in tumours with
poorly specified sites might have indicated improvements in
diagnosis during this period, which would therefore lead to
increased rates of gliomas at the temporal lobe and at other
specified sites. The fact that the rate of increase did not change
substantially after 1996 for gliomas at the temporal lobe and at
other specified sites suggests that phone use was not a
contributing factor.
The generally flat trend in incidence could have masked an
increasing glioma risk associated with mobile phone use that
hadbeencounterbalancedbyafallinincidenceduetoreductions
in other hypothetical exposures associated with excess risk of
glioma. However, the increase in phone use during the study
period would probably not have cancelled out the overall
reduction in glioma rates due to speculative other contributing
factors. Finally, risks of glioma in small susceptible subgroups
might not have been detectable in aggregate population risks.
We focused on non-Hispanic white people, because black and
Hispanic white people are known to have lower rates of brain
tumours
13 and also make up variable proportions of the
underlyingSEERpopulation,asseenwiththerapidlyincreasing
proportionofHispanicwhitepeopleinthelargestSEERregistry
(Los Angeles). However, analyses in additional ethnic groups
have produced similar results (web appendix, tables A6-A8).
Excess risks of glioma associated with mobile phone use might
not become apparent for at least 10 years. However, the latency
periods used in our models were based on observations in the
Interphone study
4 and Swedish study.
10 The Swedish study
suggested an appreciable risk of glioma within 10 years of
exposure.
Delaysincancerregistrationofgliomacasescouldhavecaused
recent incidence rates to underestimate the true rates.
CalculationsbasedonSEERdatahavesuggestedthat2008rates
ofbraincancerinwhitepeople,afteradjustmentfordelay,might
be about 4% higher than those initially reported.
18
The choice of 1992-6 as the baseline period was arbitrary, and
the interval was used because of the low level of mobile phone
subscriptions (<15% of the US population) during this period.
Resultsobtainedusingalternativebaselineperiods(1992-5and
1992-7) were very similar.
We assumed that the patterns of mobile phone use (numbers of
hours used by years of latency) were similar to the Swedish
10
and the Interphone studies.
4 To the best of our knowledge,
analogousdataforphoneusedonotexistfortheUSpopulation.
However, in view of the similar distribution of hours of use by
latency period in the Swedish
10 and Interphone studies
4 (tables
2 and 3), we would not expect any patterns of use in the US
population to be substantially different from those considered
in these two studies.
Another weakness was that the estimated cumulative hours of
use was for the period 1997-2003 for the Swedish study
10 or
2000-4 for the Interphone study,
4 while incidence trends in our
analysis were predicted from 1997 to 2008. Owing to the
additional four or five years of incidence included in our study,
asubstantiallylargerproportionofthemobilephoneuserswould
have reached the numbers of hours of phone use in the highest
exposurecategoriesoftheSwedish
10andtheInterphonestudies,
4
as well as longer latency periods. The cumulative hours of use
amongparticipantsintheInterphonestudywererecordedmostly
in 1980-2004, when mobile phone use was less common, more
expensive, and less a part of daily life than it is in the more
recent years of the present study. Use of the estimated
cumulative hours of use from the Swedish
10 and Interphone
4
studieswouldhaveresultedinourunderestimatingthepredicted
change in the incidence trends. However, this would only
appreciablyaffectourresultsifweassumedaminimumlatency
period shorter than 5 years.
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RESEARCHIn the Interphone study,
4 participation bias had been postulated
as an explanation for the overall reduced risk for glioma and
meningioma. Assuming that the bias was uniform across all
exposure groups, this could be eliminated by using the
renormalising strategy as proposed in appendix 2 of the
Interphone study.
4 The relative risks used in our study were
always assumed to be relative to non-users. But we also used
groups with the lowest phone use as a baseline category (as in
appendix 2 of the Interphone study), with the assumption that
gliomaratesinthesegroupswereidenticaltothoseinnon-users.
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RESEARCHWhat is already known on this topic
The IARC recently re-evaluated brain tumour risks associated with mobile phone exposure and classified microwave radiation produced
by mobiles phones as a possible human carcinogen, largely based on relative risks reported by two epidemiological studies, the 2010
Interphone study and a 2011 Swedish study by Hardell and colleagues
However, trends in brain cancer incidence have not mirrored the substantial increase in mobile phone use since the mid-1990s, and
have generally remained constant
What this study adds
We compared projected rates with observed rates of glioma incidence by also considering the effect of detailed latency distribution and
patterns of mobile phone use
Based on relative risks from the Swedish study, predicted rates of glioma were much higher than (and therefore statistically inconsistent
with) observed rates. However, based on relative risks from the Interphone study, projected rates could be consistent with the observed
data
Tables
Table 1| Numbers of malignant glioma cases and person-years at risk in study population
Number of cases ICD-3 morphology code ICD-3 topography code Endpoint
24 813 9380-9480 — All glioma
19 920 9400, 9401, 9410, 9411, 9420, 9421, 9424, 9440-9442 — Astrocytoma
Primary anatomical site
5147 — C71.2 Temporal lobe
13 457 — C71.0, C71.1, C71.3-71.7 Other specified site
6209 — C71.8, C71.9 Poorly specified site
WHO classification
4821 9391, 9393, 9400, 9410, 9411, 9420, 9421, 9424, 9450 — Low grade
17 459 9390, 9392, 9401, 9423, 9430, 9440-9442, 9451, 9470-9474 — High grade
2533 9380-9383, 9394, 9460, 9480 — Grade unspecified
295 348 464 — — Total person-years at risk
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RESEARCHTable 2| Relative risk of glioma (and astrocytoma) from the Swedish study10
Cumulative duration of mobile phone use (h)
Latency period (years before reference date)* >74 h ≤74 h
1-4
1.0 (1.1) 1.3 (1.3) Relative risk
203 (203) 368 (368) Controls
5-9
1.2 (1.3) 1.4 (1.5) Relative risk
182 (182) 104 (104) Controls
≥10
2.7 (3.1) 2.2 (2.7) Relative risk
96 (96) 10 (10) Controls
*The Swedish study described latency periods as “>1-5”, “>5-10”, and “>10” years. Although we used periods of 1-4, 5-9, and ≥10 years, very similar results were
obtained if we interpreted periods as 2-5, 6-10, and ≥11 years (as would be possible if latency was interpreted to be an integral variable).
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RESEARCHTable 3| Relative risk of glioma from the Interphone study4
Cumulative duration of mobile phone use (h) Latency period (years before reference date)
≥1640 360-1639.9 115-359.9 5-114.9 <5 Never use
1-4
3.77 0.75 0.74 0.82 0.68 1.00 Relative risk
8 95 154 533 182 1078 Controls
5-9
1.28 0.72 0.71 0.86 0.86 — Relative risk
73 204 192 208 13 — Controls
≥10
1.34 0.91 0.89 0.63 1.13 — Relative risk
73 90 42 25 2 — Controls
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RESEARCHTable 4| Relative risk* of glioma from appendix 2 of the Interphone study4
No of controls Relative risk
Time since start of regular use of mobile phone (years)
159 1 1-1.9
451 1.68 2-4
491 1.54 5-9
150 2.18 10+
Cumulative time spent on mobile phone call (h)
114 1 <5
124 0.88 5.0-12.9
118 1.37 13-30.9
126 1.13 31-60.9
135 1.06 61-114.9
119 1.13 115-199.9
138 1.00 200-359.9
139 1.17 360-734.9
125 1.09 735-1639.9
113 1.82 1640+
Cumulative number of calls
102 1 <150
123 0.95 150-349
148 0.85 350-749
111 1.19 750-1399
134 1.10 1400-2549
124 1.19 2550-4149
122 1.02 4150-6799
147 1.13 6800-12 799
120 1.49 12 800-26 999
120 1.31 27 000+
*Relative to low use categories of mobile phone users.
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RESEARCHTable 5| Comparison of observed rates of glioma in non-Hispanic white people in 2008 with projected rates for 2008 based on relative risks,
periods of latency, and cumulative hours of phone use from the Swedish study (table 2)10 and Interphone study (table 3)4
Interphone study, relative risk>1 Interphone study Swedish study
2008 observed
rate Endpoint
Difference from
2008 observed
rate (%)
Projected 2008
rate
Difference from
2008 observed
rate (%)
Projected 2008
rate
Difference
from 2008
observed rate
(%)
Projected 2008
rate
3.2 18.2 (17.3 to 19.3) −6.5 16.5 (15.6 to 17.5) 44.5 25.5 (24.2 to 27.0) 17.7 (16.5 to
19.0)
All glioma
4.4 17.3 (16.3 to 18.3) −5.4 15.6 (14.8 to 16.6) 58.3 26.1 (24.7 to 27.7) 16.5 (15.3 to
17.8)
Astrocytoma
Primary anatomical site
−6.8 4.0 (3.6 to 4.5) −15.5 3.7 (3.3 to 4.1) 30.6 5.6 (5.1 to 6.3) 4.3 (3.8 to 4.9) Temporal lobe
−5.9 8.5 (7.8 to 9.2) −14.7 7.7 (7.1 to 8.4) 31.7 11.9 (10.9 to 13.0) 9.0 (8.1 to 10.1) Other specified
location
39.4 5.9 (5.3 to 6.5) 26.3 5.3 (4.8 to 5.9) 95.2 8.2 (7.5 to 9.1) 4.2 (3.7 to 4.8) Poorly specified
location
WHO classification
54.4 2.9 (2.6 to 3.2) 39.9 2.6 (2.3 to 2.9) 116.2 4.0 (3.6 to 4.5) 1.9 (1.6 to 2.2) Low grade
−5.4 14.4 (13.5 to 15.3) −14.2 13.0 (12.3 to 13.9) 32.5 20.2 (18.9 to 21.4) 15.2 (14.0 to
16.5)
High grade
−12.4 0.9 (0.8 to 1.0) −20.6 0.8 (0.7 to 0.9) 22.7 1.2 (1.1 to 1.4) 1.0 (0.8 to 1.2) Grade
unspecified
Data are rate (95% confidence interval) per 100 000 people per year unless stated otherwise.
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RESEARCHTable 6| Projected rates of glioma for 2008, based on relative risks from appendix 2 of the Interphone study (table 4)4
Interphone study, appendix 2, relative risk>1 Interphone study, appendix 2
Projected rates
Difference from 2008 observed rate
(%)* Projected 2008 rate
Difference from 2008 observed
rate (%)* Projected 2008 rate
10.3 19.5 (18.4 to 20.6) 10.3 19.5 (18.4 to 20.6) Time since start of regular use (years)
Mobile phone use (h)
14.5 20.2 (19.1 to 21.4) 13.4 20.1 (19.0 to 21.2) 1 year latency
9.0 19.3 (18.2 to 20.4) 8.4 19.2 (18.1 to 20.3) 5 year latency
3.8 18.4 (17.4 to 19.4) 3.5 18.3 (17.3 to 19.4) 10 year latency
Mobile phone calls (no)
11.9 19.8 (18.7 to 20.9) 9.9 19.4 (18.4 to 20.6) 1 year latency
7.4 19.0 (18.0 to 20.1) 6.2 18.8 (17.8 to 19.9) 5 year latency
3.1 18.2 (17.2 to 19.3) 2.6 18.1 (17.2 to 19.2) 10 year latency
Data are rates (95% confidence interval) per 100 000 people per year unless stated otherwise.
*Compared with observed 2008 rate of 17.7 (16.5 to 19.0).
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RESEARCHTable 7| Trends in SEER glioma rates for non-Hispanic white people over the period 1992-2008
Rate (% per year, 95% CI) Endpoint
−0.02 (−0.28 to 0.25) Glioma
−0.21 (−0.50 to 0.07) Astrocytoma
Primary anatomical site
0.73 (0.23 to 1.23) Temporal lobe
0.79 (0.40 to 1.19) Other specified location
−2.35 (−2.81 to −1.89) Poorly specified location
WHO classification
−3.02 (−3.49 to −2.54) Low grade
0.64 (0.33 to 0.95) High grade
1.21 (0.63 to 1.79) Grade unspecified
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RESEARCHFigures
Fig 1 Mobile phone subscriptions per capita in the US, by year
25
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e1147 doi: 10.1136/bmj.e1147 (Published 8 March 2012) Page 13 of 16
RESEARCHFig 2 Observed and projected rates (95% CI) of malignant glioma in non-Hispanic white people, by latency period and
various assumed levels of relative risk associated with ever using a phone
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RESEARCHFig 3 Observed and projected rates (95% CI) of malignant glioma in non-Hispanic white people, by histological type and
WHO grade of glioma, using the relative risks, periods of latency, and cumulative hours of phone use from the Swedish
study
10 and Interphone study
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RESEARCHFig 4 Observed and projected rates (95% CI) of malignant glioma in non-Hispanic white people, by tumour location, using
the relative risks, periods of latency, and cumulative hours of phone use from the Swedish study
10 and Interphone study
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RESEARCH